Imagin Medical, Inc., headquartered in Vancouver, British Columbia, is a developer of advanced imaging systems for the detection and management of bladder cancer and other urologic conditions. The company’s flagship TriSens Imaging Platform integrates white light, blue light and near-infrared fluorescence capabilities into a single endoscopic system. By combining photodynamic diagnosis and real-time fluorescence imaging, the platform is designed to improve visualization of tumor margins and aid urologists in early-stage detection and resection procedures.
Since its inception, Imagin Medical has built its offering around a robust intellectual property portfolio, including patents covering the use of porphyrin-based contrast agents and multi-modal imaging techniques. The company secured FDA 510(k) clearance for its TriSens System and obtained CE Mark approval for distribution across the European Union. Imagin Medical continues to refine its hardware and software suite to enhance image clarity and streamline operating room workflows.
Imagin Medical markets its systems primarily to hospitals and ambulatory surgery centers across North America, Europe and select international markets. The company collaborates with leading academic institutions and urology-focused research centers to validate clinical efficacy, develop best-practice protocols and explore new indications beyond bladder cancer, such as upper tract urothelial carcinoma.
The executive team at Imagin Medical comprises seasoned professionals with extensive backgrounds in medical device development, regulatory affairs and commercial operations. Management remains focused on expanding its sales network, driving adoption among urologists and advancing next-generation imaging innovations to address unmet needs in endoscopic oncology.
AI Generated. May Contain Errors.
